The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Strominnate Therapeutics

Strominnate Therapeutics logo.

 

New biotech startup Strominnate Therapeutics is founded by researcher Tania Ramos Moreno, aiming to treat diseases in the nervous system. Their main focus is a new drug product for treating glioblastoma multiforme, the most deadly brain tumor in adults with only palliative care available.

Strominnate Therapeutics drug candidate is derived from a recently discovered human immune cell and exhibits antitumoral and tissue modulatory properties. In preclinical models, it has been shown to delay tumor progression and extend survival time, and – importantly – modulate the tumor tissue to respond efficiently to immunotherapy.

Strominnate Therapeutics hopes to make immunotherapy effective in therapy-resistant patients. 

 

Strominnate Therapeutics website

 

 

Strominnate Therapeutics

Effective treatments for tumors and conditions of the nervous system.

 

Founded by Tania Ramos-Moreno.

Portfolio company since 2021.

 

LU Holding Portfolio Manager:

eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie Thordarson), phone +46 46 222 15 59

1 Apr 2022